NAV

Stem-cell derived exosome vesicle products

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Stem-cell derived exosome vesicle products
Accession Number
DB15743
Description

Mesenchymal stem cells (MSCs) exert their therapeutic effects through multiple modalities, including paracrine factors such as exosomes. Exosomes are nanometer-sized, membrane-bound vesicles secreted for the purpose of cell-cell communication. Once secreted into extracellular fluid, exosomes are taken up by their target cells or carried to distant target sites. Various bioactive molecules (including lipids, proteins, mRNAs, and tRNAs) are used to enrich exosomes. While many contain a conserved set of proteins, they also carry unique tissue type-specific proteins. These products originate from multiple cellular types, including immunocytes, tumor cells, and mesenchymal stem cells (MSCs) originating from various tissues.

Exosomes from MSCs carry cytokines and growth factors, like TGFB1, IL-6, IL-10, and hepatocyte growth factor (HGF); all are shown to be immunomodulatory. These exosomes can also consist of VEGF and matrix metalloproteinase-9 (MMP-9) which aid in angiogenesis and tissue repair.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
  • DB-001
  • Stem-cell derived exosome vesicles
  • Stem-cell derived extracellular vesicle products
  • Stem-cell derived extracellular vesicles
External IDs
  • Stem-cell derived exosome vesicle products

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

Exosomes are a novel cell-therapy currently investigated for the treatment of liver, kidney, cardiovascular, and neurological disease. They are messengers in intercellular communication through their ability to secrete bioactive lipids, proteins, and RNAs to target sites. As they can carry unique proteins and cytokines, exosomes are involved in both physiological and pathological processes. Therapeutically, MSC-derived exosomes can restore tissue homeostasis, and enable tissue recovery, repair, and regeneration.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Saha P, Sharma S, Korutla L, Datla SR, Shoja-Taheri F, Mishra R, Bigham GE, Sarkar M, Morales D, Bittle G, Gunasekaran M, Ambastha C, Arfat MY, Li D, Habertheuer A, Hu R, Platt MO, Yang P, Davis ME, Vallabhajosyula P, Kaushal S: Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium. Sci Transl Med. 2019 May 22;11(493). pii: 11/493/eaau1168. doi: 10.1126/scitranslmed.aau1168. [PubMed:31118291]
  2. Lai RC, Yeo RW, Lim SK: Mesenchymal stem cell exosomes. Semin Cell Dev Biol. 2015 Apr;40:82-8. doi: 10.1016/j.semcdb.2015.03.001. Epub 2015 Mar 9. [PubMed:25765629]
  3. Yin K, Wang S, Zhao RC: Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm. Biomark Res. 2019 Apr 4;7:8. doi: 10.1186/s40364-019-0159-x. eCollection 2019. [PubMed:30992990]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Not Yet RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19) / Viral Pneumonia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 15:13 / Updated on September 19, 2020 20:19